[Albumin-myoestatosis gauge assisted by an artificial intelligence tool as a prognostic factor in patients with metastatic colorectal-cancer].

IF 1.1 4区医学 Q3 BUSINESS

Nutricion hospitalaria Pub Date : 2025-06-06 DOI:10.20960/nh.05687

Daniel de Luis Román, David Primo, Olatz Izaola Jáuregui, Israel Sánchez Lite, Juan José López Gómez

{"title":"[Albumin-myoestatosis gauge assisted by an artificial intelligence tool as a prognostic factor in patients with metastatic colorectal-cancer].","authors":"Daniel de Luis Román, David Primo, Olatz Izaola Jáuregui, Israel Sánchez Lite, Juan José López Gómez","doi":"10.20960/nh.05687","DOIUrl":null,"url":null,"abstract":"Objectives: to evaluate the prognostic role of the marker albumin-myosteatosis (MAM) in Caucasian patients with metastatic colorectal cancer.Material and methods: this study involved 55 consecutive Caucasian patients diagnosed with metastatic colorectal cancer. CT scans at the L3 vertebral level were analyzed to determine skeletal muscle cross-sectional area, skeletal muscle index (SMI), and skeletal muscle density (SMD). Bioelectrical impedance analysis (BIA) (phase angle, reactance, resistance, and SMI-BIA) was used. Albumin and prealbumin were measured. The albumin-myosteatosis marker (AMM = serum albumin (g/dL) × skeletal muscle density (SMD) in Hounsfield units (HU) was calculated. Survival was estimated using the Kaplan-Meier method and comparisons between groups were performed using the log-rank test.Results: the median age was 68.1 ± 9.1 years. Patients were divided into two groups based on the median MAM (129.1 AU for women and 156.3 AU for men). Patients in the low MAM group had significantly reduced values of phase angle and reactance, as well as older age. These patients also had higher rates of malnutrition by GLIM criteria (odds ratio: 3.8; 95 % CI = 1.2-12.9), low muscle mass diagnosed with TC (odds ratio: 3.6; 95 % CI = 1.2-10.9) and mortality (odds ratio: 9.82; 95 % CI = 1.2-10.9). The Kaplan-Meir analysis demonstrated significant differences in 5-year survival between MAM groups (patients in the low median MAM group vs. patients in the high median MAM group), (HR: 6.2; 95 % CI = 1.10-37.5).Conclusion: the marker albumin-myosteatosis (MAM) may function as a prognostic marker of survival in Caucasian patients with metastatic CRC.","PeriodicalId":19385,"journal":{"name":"Nutricion hospitalaria","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutricion hospitalaria","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20960/nh.05687","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BUSINESS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: to evaluate the prognostic role of the marker albumin-myosteatosis (MAM) in Caucasian patients with metastatic colorectal cancer.

Material and methods: this study involved 55 consecutive Caucasian patients diagnosed with metastatic colorectal cancer. CT scans at the L3 vertebral level were analyzed to determine skeletal muscle cross-sectional area, skeletal muscle index (SMI), and skeletal muscle density (SMD). Bioelectrical impedance analysis (BIA) (phase angle, reactance, resistance, and SMI-BIA) was used. Albumin and prealbumin were measured. The albumin-myosteatosis marker (AMM = serum albumin (g/dL) × skeletal muscle density (SMD) in Hounsfield units (HU) was calculated. Survival was estimated using the Kaplan-Meier method and comparisons between groups were performed using the log-rank test.

Results: the median age was 68.1 ± 9.1 years. Patients were divided into two groups based on the median MAM (129.1 AU for women and 156.3 AU for men). Patients in the low MAM group had significantly reduced values of phase angle and reactance, as well as older age. These patients also had higher rates of malnutrition by GLIM criteria (odds ratio: 3.8; 95 % CI = 1.2-12.9), low muscle mass diagnosed with TC (odds ratio: 3.6; 95 % CI = 1.2-10.9) and mortality (odds ratio: 9.82; 95 % CI = 1.2-10.9). The Kaplan-Meir analysis demonstrated significant differences in 5-year survival between MAM groups (patients in the low median MAM group vs. patients in the high median MAM group), (HR: 6.2; 95 % CI = 1.10-37.5).

Conclusion: the marker albumin-myosteatosis (MAM) may function as a prognostic marker of survival in Caucasian patients with metastatic CRC.

查看原文本刊更多论文

[人工智能工具辅助的白蛋白-肌定型仪作为转移性结直肠癌患者的预后因素]。

目的：探讨白蛋白-肌骨增生症（MAM）在高加索转移性结直肠癌患者预后中的作用。材料和方法：本研究纳入55例连续诊断为转移性结直肠癌的高加索患者。分析L3椎体水平的CT扫描以确定骨骼肌横截面积、骨骼肌指数（SMI）和骨骼肌密度（SMD）。采用生物电阻抗分析（BIA）（相角、电抗、电阻和SMI-BIA）。测定白蛋白和前白蛋白。计算Hounsfield单位（HU）白蛋白-肌骨化标志物（AMM =血清白蛋白（g/dL） ×骨骼肌密度（SMD））。生存率采用Kaplan-Meier法估计，组间比较采用log-rank检验。结果：中位年龄为68.1±9.1岁。根据中位MAM（女性129.1 AU，男性156.3 AU）将患者分为两组。低MAM组患者的相角和电抗值明显降低，且年龄较大。根据GLIM标准，这些患者也有更高的营养不良率(优势比：3.8；95% CI = 1.2-12.9)，低肌肉量诊断为TC(优势比：3.6；95% CI = 1.2-10.9)和死亡率(优势比：9.82；95% ci = 1.2-10.9)。Kaplan-Meir分析显示，MAM组（低中位MAM组患者与高中位MAM组患者）的5年生存率存在显著差异(HR: 6.2；95% ci = 1.10-37.5)。结论：白蛋白-肌骨增生症（MAM）标记物可能作为转移性结直肠癌高加索患者生存的预后标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutricion hospitalaria 医学-营养学

CiteScore

1.90

自引率

8.30%

发文量

181

审稿时长

3-6 weeks

期刊介绍： The journal Nutrición Hospitalaria was born following the SENPE Bulletin (1981-1983) and the SENPE journal (1984-1985). It is the official organ of expression of the Spanish Society of Clinical Nutrition and Metabolism. Throughout its 36 years of existence has been adapting to the rhythms and demands set by the scientific community and the trends of the editorial processes, being its most recent milestone the achievement of Impact Factor (JCR) in 2009. Its content covers the fields of the sciences of nutrition, with special emphasis on nutritional support.